These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 39262773)
1. Widening the spectrum of players affected by genetic changes in Wilms tumor relapse. Ciceri S; Bertolotti A; Serra A; Gattuso G; Boschetti L; Capasso M; Cecchi C; Sorrentino S; Quarello P; Ciniselli CM; Verderio P; De Cecco L; Manenti G; Diomedi Camassei F; Collini P; Spreafico F; Perotti D iScience; 2024 Sep; 27(9):110684. PubMed ID: 39262773 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse. Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191 [TBL] [Abstract][Full Text] [Related]
3. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences. Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027 [TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of Ciceri S; Gamba B; Corbetta P; Mondini P; Terenziani M; Catania S; Nantron M; Bianchi M; D'Angelo P; Torri F; Macciardi F; Collini P; Di Martino M; Melchionda F; Di Cataldo A; Spreafico F; Radice P; Perotti D; Oncotarget; 2018 Sep; 9(75):34079-34089. PubMed ID: 30344923 [TBL] [Abstract][Full Text] [Related]
5. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study. Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of (Epi)genetic Predisposing Factors in a 5-Year Unselected National Wilms Tumor Cohort: A Comprehensive Clinical and Genomic Characterization. Hol JA; Kuiper RP; van Dijk F; Waanders E; van Peer SE; Koudijs MJ; Bladergroen R; van Reijmersdal SV; Morgado LM; Bliek J; Lombardi MP; Hopman S; Drost J; de Krijger RR; van den Heuvel-Eibrink MM; Jongmans MCJ J Clin Oncol; 2022 Jun; 40(17):1892-1902. PubMed ID: 35230882 [TBL] [Abstract][Full Text] [Related]
7. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082 [TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience. Hol JA; Jongmans MCJ; Sudour-Bonnange H; Ramírez-Villar GL; Chowdhury T; Rechnitzer C; Pal N; Schleiermacher G; Karow A; Kuiper RP; de Camargo B; Avcin S; Redzic D; Wachtel A; Segers H; Vujanic GM; van Tinteren H; Bergeron C; Pritchard-Jones K; Graf N; van den Heuvel-Eibrink MM; Cancer; 2021 Feb; 127(4):628-638. PubMed ID: 33146894 [TBL] [Abstract][Full Text] [Related]
9. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ; Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316 [TBL] [Abstract][Full Text] [Related]
10. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer. Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928 [TBL] [Abstract][Full Text] [Related]